AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS BEVACIZUMAB
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Primary objectives: To compare the progression-free-survival of second-line chemotherapy with Bevacizumab to second-line chemotherapy alone in patients treated with first-line chemotherapy + Bevacizumab. Primary endpoints: progression-free-survival
创建时间：
2008-01-15
